Novelion Therapeutics Inc. (NVLN) SEC Filing 8-K Material Event for the period ending Wednesday, October 2, 2019

Novelion Therapeutics Inc.

CIK: 827809 Ticker: NVLN

View differences made from one to another to evaluate Novelion Therapeutics Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Novelion Therapeutics Inc..


Assess how Novelion Therapeutics Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Novelion Therapeutics Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


Ticker: NVLN
CIK: 827809
Form Type: 8-K Corporate News
Accession Number: 0001104659-19-052993
Submitted to the SEC: Thu Oct 03 2019 4:42:03 PM EST
Accepted by the SEC: Thu Oct 03 2019
Period: Wednesday, October 2, 2019
Industry: Pharmaceutical Preparations
  1. Event for Officers
  2. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: